Neurocrine Biosciences | NBIX - Equity Capital And Reserves


Neurocrine Biosciences reported $3.25B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
ALKERMES USD 1.82B 85.86M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Cytokinetics USD -659.62M 138.5M Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Exelixis USD 2.16B 619K Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Prothena USD 280.47M 14.51M Dec/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Repligen USD 2.11B 1.66B Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Teva Pharmaceutical Industries USD 7.91B 664M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025
Xoma USD 87.94M 15.5M Sep/2025